Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 16/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482769 | 0.79 | NSD2 (0.41) | NSD2BCHE | |
| SCHEMBL483108 | 0.74 | HTR6 (0.40) | — | |
| SCHEMBL2576017 | 0.64 | BCHE (0.55) | BCHECES2 | |
| SCHEMBL27980180 | 0.64 | BCHE (0.51) | BCHECES2 | |
| SCHEMBL27557534 | 0.62 | MC4R (0.59) | BCHECES2 | |
| SCHEMBL27810920 | 0.62 | BCHE (0.61) | BCHE | |
| SCHEMBL27883387 | 0.61 | BCHE (0.53) | BCHECES2 | |
| SCHEMBL28036737 | 0.61 | BCHE (0.53) | BCHECES2 | |
| SCHEMBL18640771 | 0.61 | ALDH1A1 (0.51) | NSD2BCHE | |
| SCHEMBL13491386 | 0.61 | NSD2 (0.70) | NSD2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | NSD2 455/4885BCHE 4197/4885ADORA2A 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.